Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4071-4077

  Milne, K E N ^a   Gould, I M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; SULTAMICILLIN; TIMENTIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; MEDICAL DEVICE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; QUESTIONNAIRES; RESPIRATORY SYSTEM; STENOTROPHOMONAS MALTOPHILIA; YOUNG ADULT;

EID: 84864392129     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00072-12     Document Type: Article

References (31)

1. Bonapace CR, White RL, Friedrich LV, Bosso JA. 2000. Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time kill and checkerboard methods. Diagn. Microbiol. Infect. Dis. 38:43-50.
2. Bonfiglio G, et al. 2000. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J. Antimicrob. Chemother. 45:115-117. (Pubitemid 30060243)
3. Chandra S, et al. 2008. Stenotrophomonas maltophilia in cystic fibrosis. Chest 134(Suppl.):S57002. http://meeting.chestpubs.org/cgi/content/abstract/134/ 4/s57002.
4. Chernish RN, Aaron SD. 2003. Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr. Opin. Pulm. Med. 9:509-515. (Pubitemid 37268216)
5. Clinical and Laboratories Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing: 20th informational supplement M100-S20. CLSI, Wayne, PA.
6. Denton M, Kerr KG. 1998. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin. Microbiol. Rev. 11:57-80. (Pubitemid 28046016)
7. Dudley MN, Loutit J, Griffith DC. 2008. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr. Opin. Biotech. 19:637-643.
8. Elborn JS. 2008. Identification and management of unusual pathogens in cystic fibrosis. J. R. Soc. Med. 101(Suppl.):S2-S5.
9. Gales AC, et al. 2001. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin. Infect. Dis. 32(Suppl. 2):104-113.
10. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H. 2002. Synergy of colistin with rifampicin and trimethoprim/sulfamethoxazole on multi-drug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 44:259-263. (Pubitemid 35454100)
11. Goss CH, Burns JL. 2007. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62:360-367. (Pubitemid 46580580)
12. Goss CH, Otto K, Aitken ML, Rubenfeld GD. 2002. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 166:356-361. (Pubitemid 34864426)
13. Graff GR, Burns JL. 2002. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 121:1754-1760. (Pubitemid 34634392)
14. Krueger TS, Clark EA, Nix DE. 2001. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn. Microbiol. Infect. Dis. 41:71-78. (Pubitemid 33001462)
15. Lipuma JJ. 2010. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23:299-323.
16. MacKenzie FM, Griffiths C, Dempsey O, Devereaux G, Gould IM. 2005. Combination antibiotic susceptibility testing in cystic fibrosis. Lancet 366:1693.
17. MacKenzie FM, et al. 2004. Antibiograms of resistant Gram-negative bacteria from Scottish CF patients. J. Cyst. Fibros. 3:151-157. (Pubitemid 39194069)
18. Marchac V, Equi A, Le Bihan-Benjamin C, Hodson M, Bush A. 2004. Case-control study of Stenotrophomonas maltophilia acquisition in cystic fibrosis patients. Eur. Respir. J. 23:98-102. (Pubitemid 38088504)
19. Milne KEN, Gould IM. 2010. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J. Antimicrob. Chemother. 65:82-90.
20. Moriarty TF, McElnay JC, Elborn JS, Tunney MM. 2007. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Paediatr. Pulmonol. 42:1008-1017. (Pubitemid 350133395)
21. Moskowitz SM, et al. 2008. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet. Med. 10:851-868.
22. Nicodemo AC, Araujo MRE, Ruiz AS, Gales AC. 2004. In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J. Antimicrob. Chemother. 53:604-608. (Pubitemid 38499774)
23. Odds FC. 2003. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52:1. doi:10.1093/jac/dkg301. (Pubitemid 36850074)
24. Pankey GA, Ashcraft DS. 2010. In vitro synergistic/additive activity of levofloxacin with meropenem against Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 67:297-300.
25. Rowe SM, Clancy JP. 2006. Advances in cystic fibrosis therapies. Curr. Opin. Pediatr. 18:604-613. (Pubitemid 44747152)
26. Saiman L. 2007. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8:249-255. (Pubitemid 47440663)
27. San Gabriel P, et al. 2004. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 48:168-171. (Pubitemid 38040193)
28. Song W, Woo HJ, Kim JS, Lee KM. 2003. In vitro activity of β-lactams in combination with other antimicrobial agents against resistant strains of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 21:8-12. (Pubitemid 36043969)
29. Valdezate S, Vindel A, Loza E, Baquero F, Canton R. 2001. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob. Agents Chemother. 45:1581-1584. (Pubitemid 32374141)
30. Waters V, et al. 2012. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J. Cyst. Fibros. 11:8-13.
31. Zemanick ET, et al. 2010. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J. Cyst. Fibros. 9:1-16.